Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 30:9:876864.
doi: 10.3389/fmed.2022.876864. eCollection 2022.

Beyond QuantiFERON-TB Results, the Added Value of a Weak Mitogen Response

Affiliations

Beyond QuantiFERON-TB Results, the Added Value of a Weak Mitogen Response

Marine Jacquier et al. Front Med (Lausanne). .

Abstract

Introduction: While QuantiFERON-TB gold (QFT) is frequently used, little attention is paid to the mitogen response. How it could be impacted and associated with outcomes is poorly known.

Methods: Retrospective, case-control study in hospitalized patients who underwent QFT testing in two hospitals between 2016 and 2019. We defined two groups of cases with either negative [interferon (IFN)-γ ≤ 0.5 IU/ml, official threshold] or weak (0.5-2 IU/ml) mitogen response, and one group of controls with normal (>2 IU/ml) mitogen response.

Results: A total of 872 patients were included. An ongoing infection was independently associated with both a negative (RR = 4.34; 95% CI = 2.94-6.41) and a weak mitogen response (RR = 2.44; 95% CI = 1.66-3.58). Among tuberculosis patients, a weak mitogen response was associated with a false-negative QFT result (75%) compared to a normal response (20%). Decreasing mitogen response (normal, weak and negative, respectively) was associated with increasing length of hospital stay [median (interquartile range) 5 (3-13), 11 (5-21) and 15 (10-30) days; p < 0.001] and increasing hospital mortality (3, 7, and 15%; p < 0.001).

Conclusion: Clinicians should take notice of the mitogen response since IFN-γ concentrations lower than <2 IU/ml were associated with false-negative QFT results in tuberculosis patients, independently associated with ongoing infections, and could be associated with worse prognosis.

Keywords: QuantiFERON; infection; mitogen; mortality; outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Inverse correlation between INF-γ mitogen response and C-reactive protein levels in hospitalized patients. Correlation between INF-γ mitogen response of QFT and C-reactive protein levels was assessed in hospitalized patients included in the study and with available C-reactive protein data (n = 825); Spearman test. NB: IFN-γ, interferon γ, QFT, QuantiFERON-TB Gold.
FIGURE 2
FIGURE 2
Clinical outcomes of 872 hospitalized patients according to the mitogen response of QFT (negative, weak or normal). Proportion of patients with infectious complications during hospital stay after QFT sampling (A), intensive care unit (ICU) admissions (B), in-hospital mortality (C) and the median (interquartile range) hospital length of stay (D) were recorded and represented according to the mitogen response: negative (IFN-γ ≤ 0.5 IU/ml), weak (IFN-γ = 0.5–2 IU/ml) and “normal” (IFN-γ > 2 IU/ml). NB: QFT, QuantiFERON-TB Gold; ICU, intensive care unit; IFN-γ, interferon γ. Comparisons were made between the 3 groups using Kruskall-Wallis test for continuous variable, and the Chi-square test for qualitative variables. Post-hoc 2 × 2 comparisons were performed using the Wilcoxon Mann-Whitney test and Chi-square test as appropriate. False Discovery Rate post hoc correction for multiple comparisons was used and P value reported in the figure : *P < 0.05; **P < 0.01.

References

    1. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. (2018) 31:e21–18. 10.1128/CMR.00021-18 - DOI - PMC - PubMed
    1. Brown J, Kumar K, Reading J, Harvey J, Murthy S, Capocci S, et al. Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J. (2017) 50:1701267. 10.1183/13993003.01267-2017 - DOI - PubMed
    1. Lange B, Vavra M, Kern WV, Wagner D. Indeterminate results of a tuberculosis-specific interferon- release assay in immunocompromised patients. Eur Respir J. (2010) 35:1179-82. - PubMed
    1. Hradsky O, Ohem J, Zarubova K, Mitrova K, Durilova M, Kotalova R, et al. Disease activity is an important factor for indeterminate interferon-γ release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutrit. (2014) 58:320-4. 10.1097/MPG.0000000000000205 - DOI - PubMed
    1. Helwig U, Müller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohn’s Colitis. (2012) 6:419-24. 10.1016/j.crohns.2011.09.011 - DOI - PubMed

LinkOut - more resources